Evidence map›Paper›PMID 41276109›Full record

ArticleCancer letters2026

Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression.

Md Arafat Khan, Parvez Khan, Mahek Fatima, Asad Ur Rehman, Laiba Anwar, Zahraa Wajih Alsafwani, Aatiya Ahmad, Mohammad Ali Abbas Zaidi, Jesse L Cox, Areem Zahid and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Md Arafat KhanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Parvez KhanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA. Electronic address: parvez.khan@unmc.edu.
Mahek FatimaDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Asad Ur RehmanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Laiba AnwarDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Zahraa Wajih AlsafwaniDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Aatiya AhmadDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Mohammad Ali Abbas ZaidiDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Jesse L CoxDepartment of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Areem ZahidDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Sameer MohiuddinDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Sung Hoon KimDepartment of Chemistry and Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Juan A Santamaria-BarriaDepartment of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
Imayavaramban LakshmananDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Benita S KatzenellenbogenDepartment of Molecular and Integrative Physiology and Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
John A KatzenellenbogenDepartment of Chemistry and Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Apar K GantiDivision of Oncology-Hematology, Department of Internal Medicine, VA-Nebraska Western Iowa Health Care System, And Division of Oncology-Hematology, University of Nebraska Medical Center, Omaha, NE-68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Surinder K BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE-68198, USA; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE-68198, USA.
Mohd Wasim NasserDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA; Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE-68198, USA. Electronic address: wasim.nasser@unmc.edu.

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Lynette M Smith · 1985 to 2026
$55.0M
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancerR01CA273349 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., PONNUSAMY, MOORTHY P. · 2022 to 2025
$2.7M
Novel approach to attenuate small cell lung cancer growth and metastasisR01CA218545 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI NASSER, MOHD WASIM · 2018 to 2022
$2.6M
Targeting MUC5AC mucin in breast cancer brain metastasisR01CA241752 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI NASSER, MOHD WASIM · 2021 to 2025
$2.3M
Connectivity mapping identified novel combination therapy for glioblastomaR01CA273319 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., SHONKA, NICOLE · 2022 to 2025
$2.2M
NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA218545NCI NIH HHS R01 CA241752NCI NIH HHS R01 CA273319NCI NIH HHS R01 CA273349
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is a lethal lung malignancy, which is associated with distant metastasis and chemoresistance. Due to the limited availability of targeted therapies, identifying a potential therapeutic target is a pressing unmet need in SCLC. Single-cell and bulk-transcriptomic datasets were analyzed that revealed FOXM1 as a potential targeting candidate in SCLC. High FOXM1 expression was observed in human and murine SCLC tissues and cell lines. Interestingly, chemoresistant (CR) SCLC cells exhibited substantially higher FOXM1 expression compared to naïve SCLC. Furthermore, FOXM1 inhibition in combination with platinum-based chemotherapy showed synergistic anticancer effects in vitro and in vivo xenograft and spontaneous (RPM: RB1

Indexed as

Forkhead Box Protein M1Lung NeoplasmsSmall Cell Lung CarcinomaAnimalsCD8-Positive T-LymphocytesCell Line, TumorDisease ProgressionDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMiceSignal TransductionTumor MicroenvironmentXenograft Model Antitumor AssaysForkhead Box Protein M1FOXM1 protein, humanChemotherapeutic resistanceFOXM1 inhibitorsMetastasisSmall cell lung cancerT cell activation

Identifiers

PMID41276109
PMCPMC13105206

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.